Press releases
- Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
- Oragenics, Inc. Files 10K and Provides Company Update
- Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
- Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
Key statistics
On Friday, Oragenics Inc (0A64:LSE) closed at 2.12, 108.77% above the 52 week low of 1.02 set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 2.12 |
Average volume | 1.70k |
---|---|
Shares outstanding | 4.48m |
Free float | 3.44m |
P/E (TTM) | -- |
Market cap | 9.05m USD |
EPS (TTM) | -7.98 USD |
Data delayed at least 20 minutes, as of May 31 2024 15:55 BST.
More ▼